- Roche (RHHBY, Financial) launches Elecsys PRO-C3 test for evaluating liver fibrosis in MASLD patients.
- The test provides results in 18 minutes on Roche's cobas analyzers, offering a faster diagnostic method.
- MASLD impacts around 30% of the global population, with the test addressing a critical need in liver disease diagnosis.
Roche (RHHBY) has unveiled its Elecsys PRO-C3 test, a groundbreaking diagnostic tool for evaluating the severity of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). This condition affects approximately 30% of the global population and contributes to one in every 25 deaths worldwide.
Developed in collaboration with Nordic Bioscience, the Elecsys PRO-C3 test delivers results in just 18 minutes using Roche's cobas analyzers. This quick turnaround is crucial for timely intervention and management, potentially improving patient outcomes.
The test works in conjunction with the ADAPT formula, weighing factors such as age, diabetes status, PRO-C3 levels, and platelet count to distinguish between various levels of fibrosis severity. This allows clinicians to identify significant fibrosis, advanced fibrosis, and cirrhosis, thereby aiding in the determination of appropriate treatment pathways.
Initially, the calculation of the ADAPT score will be manual. However, Roche plans to streamline the diagnostic process further by launching software for automated score calculation later in 2025. This innovation is expected to reduce reliance on invasive biopsies and improve diagnostic efficiency, making it a vital tool in addressing the rising prevalence of MASLD and its associated healthcare burdens.
